ATOS
Atossa Therapeutics, Inc.0.7247
+0.0100+1.4%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
93.61MP/E (TTM)
-Basic EPS (TTM)
-0.23Dividend Yield
0%Recent Filings
10-K
FY2025 results
Atossa Therapeutics posted FY2025 ended December 31, 2025 results as a clinical-stage biopharma with no revenue disclosed in the 10-K, focusing on (Z)-endoxifen Phase 2 trials including Karisma-(Z)-endoxifen that wrapped in June 2024 showing 17.3% MBD reduction at 1mg dose vs placebo. Q4 momentum built on study database lock in September 2024, with 24-month durability data eyed for Q2 2026. No quarterly financials or EPS provided. Cash position not detailed. Executive separation in November 2025 adds overhead. Clinical timelines hinge on FDA interactions.
8-K
Q4 results: wider loss, DMD nods
Atossa Therapeutics reported Q4 and full-year 2025 results on March 25, 2026, posting a $37.1M operating loss, up from $27.6M in 2024, driven by $21.2M R&D spend—a 50% jump on (Z)-endoxifen trials. Cash dropped to $41.3M from $71.1M. FDA granted Rare Pediatric Disease and Orphan Drug designations for DMD. Hired two MDs to bolster clinical push. Cash burn accelerates.
8-K
New $50M ATM agreement
Atossa Therapeutics terminated its prior ATM agreement with Jefferies on February 19, 2026, with no sales or penalties, then inked a fresh $50 million ATM pact with Rodman & Renshaw on February 20. Shares will sell opportunistically on Nasdaq. New shelf taps clinical development and general purposes. No sales obligation exists.
8-K
Regains Nasdaq compliance
Atossa Therapeutics regained Nasdaq compliance on February 17, 2026, after its stock held a $1.00 minimum closing bid for 10 straight days ending February 13. This resolves a deficiency flagged in February 2025 and extended to the deadline. Shares stay listed on Nasdaq Capital Market. Compliance secured.
8-K
2026 shareholder letter issued
Atossa Therapeutics issued its 2026 Letter to Shareholders on February 11, highlighting 2025 FDA clarity on (Z)-endoxifen's breast cancer paths and Rare Pediatric/Orphan Drug designations for DMD. I-SPY 2 combo data due H1 2026; metastatic paused for higher-ROI focus. Cash tops $40 million. Nasdaq compliance regained.
IPO
Employees
Sector
Industry
ACTU
Actuate Therapeutics, Inc.
6.96+0.10
ANIX
Anixa Biosciences, Inc.
3.57+0.31
ATRA
Atara Biotherapeutics, Inc.
17.58-0.37
ATXS
Astria Therapeutics, Inc.
12.87-0.05
BCAB
BioAtla, Inc.
0.76-0.01
BCAX
Bicara Therapeutics Inc.
18.15-0.21
GRTX
Galera Therapeutics, Inc.
0.02+0.00
OLMA
Olema Pharmaceuticals, Inc.
34.28-1.55
OSTX
OS Therapies Incorporated
1.62-0.05
ZNTL
Zentalis Pharmaceuticals, Inc.
1.38-0.02